HomeNewsNovel research on Amoebic Gill Disease (AGD)

6 March 2017

Novel research on Amoebic Gill Disease (AGD)

Benchmark’s Fish Vet Group, Ireland, highlight novel work on gill disease in salmon in the journal Aquaculture.

This is the first study to assess the protein profile in the gills of Atlantic salmon smolts during the development of amoebic gill disease (AGD), with the aim of detecting potential targets for diagnosis and treatment.

Amoebic gill disease (AGD), caused by the marine ectoparasite Neoparamoeba perurans, is one of the most significant infectious diseases for Atlantic salmon aquaculture and can severely compromise the host if left untreated.

The research was undertaken by the Galway-Mayo Institute of Technology, Vet Aqua International and Benchmark’s Fish Vet Group.

Gill disease is one of the biggest challenges to production for most salmon farming nations.

Gill disease is something we need to address urgently as it has a global impact even greater than sea lice. Many farms struggle to manage sea lice because of gill problems. Gill disease is dynamic, changing all the time, and there are many knowledge gaps. Scientists have ‘good tools’ at their disposal, but don’t necessarily know how to use them to effectively control disease outbreaks. This vital research contributes to closing these gaps.

Hamish Rodger

Global Managing Director of Fish Vet Group